Tea and Parkinson's disease: Constituents of tea synergize with antiparkinsonian drugs to provide better therapeutic benefits

Neurochemistry International

Volumn 89, Issue , 2015, Pages 181-190

  Dutta, Debashis ^a   Mohanakumar, Kochupurackal P ^a  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

Author keywords

Catechins; Catechol O methyl transferase inhibition; Phophorylated ERK1 2; Polyphenols; Rasagiline; Theoflavin

Indexed keywords

ADENOSINE A2A RECEPTOR ANTAGONIST; ANTIPARKINSON AGENT; DOPAMINE RECEPTOR; LEVODOPA; POLYPHENOL; POSTSYNAPTIC RECEPTOR; RASAGILINE; TEA;

ANTIOXIDANT ACTIVITY; BEVERAGE; BRAIN DEPTH STIMULATION; BRAIN MITOCHONDRION; CATABOLISM; DIET; DISEASE COURSE; DOPAMINERGIC NERVE CELL; HUMAN; META ANALYSIS (TOPIC); METABOLIC REGULATION; NERVE CELL NECROSIS; NEURAL STEM CELL TRANSPLANTATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; TEA; ANIMAL; DRUG EFFECTS; DRUG POTENTIATION; METABOLISM;

ANIMALS; ANTIPARKINSON AGENTS; DOPAMINERGIC NEURONS; DRUG SYNERGISM; HUMANS; LEVODOPA; PARKINSON DISEASE; POLYPHENOLS; TEA;

EID: 84942292877     PISSN: 01970186     EISSN: 18729754     Source Type: Journal    
DOI: 10.1016/j.neuint.2015.08.005     Document Type: Review

References (147)

1. S. Acosta, J. Jernberg, C.D. Sanberg, P.R. Sanberg, B.J. Small, C. Gemma, and P.C. Bickford NT-020, a natural therapeutic approach to optimize spatial memory performance and increase neural progenitor cell proliferation and decrease inflammation in the aged rat Rejuv. Res. 13 2010 581 588
2. M. Alam, and W.J. Schmidt Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats Behav. Brain Res. 136 2002 317 324
3. L.M. Ambani, M.H. Van Woert, and S. Murphy Brain peroxidase and catalase in Parkinson disease Arch. Neurol. 32 1975 114 118
4. A. Anandhan, U. Janakiraman, and T. Manivasagam Theaflavin ameliorates behavioral deficits, biochemical indices and monoamine transporters expression against subacute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mouse model of parkinson's disease Neuroscience 218 2012 257 267
5. A. Anandhan, K. Tamilselvam, T. Radhiga, S. Rao, M.M. Essa, and T. Manivasagam Theaflavin, a black tea polyphenol, protects nigral dopaminergic neurons against chronic MPTP/probenecid induced Parkinson's disease Brain Res. 1433 2012 104 113
6. A. Anandhan, M.M. Essa, and T. Manivasagam Therapeutic attenuation of neuroinflammation and apoptosis by black tea theaflavin in chronic MPTP/probenecid model of Parkinson's disease Neurotox. Res. 23 2013 166 173
7. R. Aneja, K. Odoms, A.G. Denenberg, and H.R. Wong Theaflavin, a black tea extract, is a novel anti-inflammatory compound Crit. Care. Med. 32 2004 2097 2103
8. M.T. Armentero, R. Fancellu, G. Nappi, P. Bramanti, and F. Blandini Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodent model of Parkinson's disease Neurobiol. Dis. 22 2006 1 9
9. A. Ashenef Essential and toxic metals in tea (Camellia sinensis) imported and produced in Ethiopia Food. Addit. Contam. Part B Surveill. 7 2013 30 36
10. S. Ayton, and P. Lei Nigral iron elevation is an invariable feature of Parkinson's disease and is a sufficient cause of neurodegeneration Biomed. Res. Int. 2014 2014 581256
11. R. Banerjee, A.A. Starkov, M.F. Beal, and B. Thomas Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis Biochim. Biophys. Acta 1792 2009 651 663
12. C. Barcia, F. Ros, M.A. Carrillo, D. Aguado-Llera, C.M. Ros, A. Gómez, C. Nombela, V. de Pablos, E. Fernández-Villalba, and M.T. Herrero Inflammatory response in Parkinsonism J. Neural. Transm. 73 2009 245 252
13. A. Bender, K.J. Krishnan, C.M. Morris, G.A. Taylor, A.K. Reeve, R.H. Perry, E. Jaros, J.S. Hersheson, J. Betts, T. Klopstock, R.W. Taylor, and D.M. Turnbull High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease Nat. Genet. 38 2006 515 517
14. V. Bonifati Genetics of Parkinson's disease - state of the art, 2013 Park. Relat. Disord. 20 Suppl. 1 2014 S23 S28
15. A. Borah, and K.P. Mohanakumar Long term L-DOPA treatment causes production of 6-OHDA in the mouse striatum: involvement of hydroxyl radical Ann. Neurosci. 16 2009 160 165
16. A. Borah, and K.P. Mohanakumar Denervated, but not innervated striatum of parkinsonian rats is sensitive to 6-hydroxydopamine production in vivo following prolonged L-DOPA administration Neurochem. Int. 56 2010 357 362
17. A. Borah, and K.P. Mohanakumar Salicylic acid protects against chronic L-DOPA -induced 6-hydroxydopamine generation in experimental model of parkinsonism Brain Res. 1344 2010 192 199
18. M.K. Borland, K.P. Mohanakumar, J.D. Rubinstein, P.M. Keeney, J. Xie, and R. Capaldi Relationships among molecular genetics and respiratory properties of Parkinson's disease cybrid cells show similarities to Parkinson's brain tissues Biochem. Biophys. Acta 1792 2009 68 74
19. M. Bousquet, M. Saint-Pierre, C. Julien, N. Salem Jr., F. Cicchetti, and F. Calon Beneficial effects of dietary omega-3 polyunsaturated fatty acid on toxin-induced neuronal degeneration in an animal model of Parkinson's disease FASEB J. 22 2008 1213 1225
20. S.G. Bowes, P.K. Clark, A.L. Leeman, C.J. O'Neill, C. Weller, P.W. Nicholson, A.A. Deshmukh, S.M. Dobbs, and R.J. Dobbs Determinants of gait in the elderly parkinsonian on maintenance levodopa/carbidopa therapy Br. J. Clin. Pharmacol. 30 1990 13 24
21. F. Cai, C.R. Li, J.L. Wu, J.G. Chen, C. Liu, Q. Min, W. Yu, C.H. Ouyang, and J.H. Chen Theaflavin ameliorates cerebral ischemia-reperfusion injury in rats through its anti-inflammatory effect and modulation of STAT-1 Mediat. Inflamm. 5 2006 30490
22. J. Cai, D. Jing, M. Shi, Y. Liu, T. Lin, Z. Xie, Y. Zhu, H. Zhao, X. Shi, F. Du, and G. Zhao Epigallocatechin gallate (EGCG) attenuates infrasound-induced neuronal impairment by inhibiting microglia-mediated inflammation J. Nutr. Biochem. 25 2014 716 725
23. A. Carlsson Treatment of Parkinson's with L-DOPA. The early discovery phase, and a comment on current problems J. Neural. Transm. 109 2002 777 787
24. M. Caruana, J. Neuner, T. Högen, F. Schmidt, F. Kamp, C. Scerri, A. Giese, and N. Vassallo Polyphenolic compounds are novel protective agents against lipid membrane damage by α-synuclein aggregates in vitro Biochim. Biophys. Acta 1818 2012 2502 2510
25. E. Cereda, M. Barichella, C. Pedrolli, and G. Pezzoli Low-protein and protein-redistribution diets for Parkinson's disease patients with motor fluctuations: a systematic review Mov. Disord. 25 2010 2021 2034
26. J. Chakraborty, U. Rajamma, N. Jana, and K.P. Mohanakumar Quercetin improves the activity of the ubiquitin-proteasomal system in 150Q mutated huntingtin-expressing cells but exerts detrimental effects on neuronal survivability J. Neurosci. Res. 2015 10.1002/jnr.23618
27. G. Chandra, P.K. Gangopadhyay, K.S. Senthil Kumar, and K.P. Mohanakumar Acute intranigral homocysteine administration produces stereotypic behavioral changes and striatal dopamine depletion in Sprague-Dawley rats Brain Res. 1075 2006 81 92
28. J. Chao, W.K. Lau, M.J. Huie, Y.S. Ho, M.S. Yu, C.S. Lai, M. Wang, W.H. Yuen, W.H. Lam, T.H. Chan, and R.C. Chang A pro-drug of the green tea polyphenol (-)-epigallocatechin-3-gallate (EGCG) prevents differentiated SH-SY5Y cells from toxicity induced by 6-hydroxydopamine Neurosci. Lett. 469 2010 360 364
29. R.K. Chaturvedi, S. Shukla, K. Seth, S. Chauhan, C. Sinha, Y. Shukla, and A.K. Agrawal Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease Neurobiol. Dis. 22 2006 421 434
30. K.R. Chaudhuri, D.G. Healy, and A.H.V. Schapira Non-motor symptoms of Parkinson's disease: diagnosis and management Lancet. Neurol. 5 2006 235 245
31. M. Chen, T. Wang, F. Yue, X. Li, P. Wang, Y. Li, P. Chan, and S. Yu Tea polyphenols alleviate motor impairments, dopaminergic neuronal injury, and cerebral a-synuclein aggregation in MPTP-intoxicated parkinsonian monkeys Neuroscience 286 2015 383 392
32. M. Chin-Chan, J. Navarro-Yepes, and B. Quintanilla-Vega Environmental pollutants as risk factors for neurodegenerative disorders: Alzheimer and Parkinson diseases Front. Cell. Neurosci. 9 2015 124
33. H.S. Cho, S. Kim, S.Y. Lee, J.A. Park, S.J. Kim, and H.S. Chun Protective effect of the green tea component, L -theanine on environmental toxins-induced neuronal cell death Neurotoxicology 29 2008 656 662
34. J.Y. Choi, C.S. Park, D.J. Kim, M.H. Cho, B.K. Jin, J.E. Pie, and W.G. Chung Prevention of nitric oxide-mediated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease in mice by tea phenolic epigallocatechin 3-gallate Neurotoxicology 23 2002 367 374
35. J. Clark, E.L. Clore, K. Zheng, A. Adame, E. Masliah, and D.K. Simon Oral N-acetyl-cysteine attenuates loss of dopaminergic terminals in alpha-synuclein overexpressing mice Plos One 5 2010 e12333
36. B.S. Connolly, and A.E. Lang Pharmacological treatment of Parkinson disease: a review JAMA 311 2014 1670 1683
37. T.M. Dawson, and V.L. Dawson Neuroprotective and neurorestorative strategies for Parkinson's disease Nat. Neurosci. 2002 1058 1061
38. T.M. Dawson, and V.L. Dawson Molecular pathways of neurodegeneration in Parkinson's disease Science 302 2003 819 822
39. D.T. Dexter, J. Sian, S. Rose, J.G. Hindmarsh, V.M. Mann, J.M. Cooper, F.R. Wells, S.E. Daniel, A.J. Lees, and A.H. Schapira Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease Ann. Neurol. 35 1994 38 44
40. A. Djamshidian, S.S. O'Sullivan, A. Tomassini, T. Foltynie, P. Limousin, I. Aviles-Olmos, T.T. Warner, A.J. Lees, and B.B. Averbeck In a rush to decide: deep brain stimulation and dopamine agonist therapy in Parkinson's disease J. Park. Dis. 4 2014 579 583
41. E.R. Dorsey, R. Constantinescu, J.P. Thompson, K.M. Biglan, R.G. Holloway, K. Kieburtz, F.J. Marshall, B.M. Ravina, G. Schifitto, A. Siderowf, and C.M. Tanner Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030 Neurology 68 2007 384 386
42. E.R. Dorsey, L.M. Deuel, C.A. Beck, I.F. Gardiner, N.J. Scoglio, J.C. Scott, F.J. Marshall, and K.M. Biglan Group patient visits for Parkinson disease: a randomized feasibility trial Neurology 76 2011 1542 1547
43. A. Effenberg, N. Stanslowsky, A. Klein, M. Wesemann, A. Haase, U. Martin, R. Dengler, C. Grothe, A. Ratzka, and F. Wegner Striatal transplantation of human dopaminergic neurons differentiated from induced pluripotent stem cells derived from umbilical cord blood using lentiviral reprogramming Cell. Transpl. 2014 10.3727/096368914X685591
44. R. Exley, and S.J. Cragg Presynaptic nicotinic receptors: a dynamic and diverse cholinergic filter of striatal dopamine neurotransmission Br. J. Pharmacol. 153 2008 283 297
45. J.P. Finberg, J. Wang, K. Bankiewicz, J. Harvey-White, I.J. Kopin, and D.S. Goldstein Increased striatal dopamine production from L-DOPA following selective inhibition of monoamine oxidase B by R(+)-N-propargyl-1-aminoindan (rasagiline) in the monkey J. Neural. Transm. 52 1998 279 285
46. K.M. Fitzpatrick, J. Raschke, and M.E. Emborg Cell-based therapies for Parkinson's disease: past, present, and future Antioxid. Redox Signal 11 2009 2189 2208
47. X. Gao, A. Cassidy, M.A. Schwarzschild, E.B. Rimm, and A. Ascherio Habitual intake of dietary flavonoids and risk of Parkinson disease Neurology 78 2012 1138 1145
48. T. Gasser Genetics of Parkinson's disease Curr. Opin. Neurol. 18 2005 363 369
49. M.E. Gegg, J.M. Cooper, K.Y. Chau, M. Rojo, A.H. Schapira, and J.W. Taanman Mitofusin 1 and mitofusin 2 are ubiquitinated in a PINK1/parkin-dependent manner upon induction of mitophagy Hum. Mol. Genet. 19 2010 4861 4870
50. C.K. Glass, K. Saijo, B. Winner, M.C. Marchetto, and F.H. Gage Mechanisms underlying inflammation in neurodegeneration Cell 140 2010 918 934
51. X. Guillot, L. Semerano, N. Saidenberg-Kermanac'h, G. Falgarone, and M.C. Boissier Vitamin D and inflammation Jt. Bone. Spine 77 2010 552 557
52. S. Guo, J. Yan, T. Yang, X. Yang, E. Bezard, and B. Zhao Protective effects of green tea polyphenols in the 6-OHDA rat model of Parkinson's disease through inhibition of ROS-NO pathway Biol. Psychiatr. 62 2007 1353 1362
53. M. Hachem, A. Géloën, A.L. Van, B. Foumaux, L. Fenart, F. Gosselet, P. Da Silva, G. Breton, M. Lagarde, M. Picq, and N. Bernoud-Hubac Efficient docosahexaenoic acid uptake by the brain from a structured phospholipid Mol. Neurobiol. 2015 10.1007/s12035-015-9228-9
54. D.J. Hampshire, E. Roberts, Y. Crow, J. Bond, A. Mubaidin, A.L. Wriekat, A. Al-Din, and C.G. Woods Kufor-Rakeb syndrome, pallido-pyramidal degeneration with supranuclear upgaze paresis and dementia, maps to 1p36 J. Med. Genet. 38 2001 680 682
55. T. Hasegawa Tyrosinase-expressing neuronal cell line as in vitro model of Parkinson's disease Int. J. Mol. Sci. 11 2010 1082 1089
56. R.A. Hauser, and M.A. Schwarzschild Adenosine A2A receptor antagonists for Parkinson's disease: rationale, therapeutic potential and clinical experience Drugs Aging 22 2005 471 482
57. H. Heikkinen, A. Varhe, T. Laine, J. Puttonen, M. Kela, S. Kaakkola, and K. Reinikainen Entacapone improves the availability of L-DOPA in plasma by decreasing its peripheral metabolism independent of L-DOPA/carbidopa dose Br. J. Clin. Pharmacol. 54 2002 363 371
58. W. Hellenbrand, A. Seidler, H. Boeing, B.P. Robra, P. Vieregge, P. Nischan, J. Joerg, W.H. Oertel, E. Schneider, and G. Ulm Diet and Parkinson's disease. I: a possible role for the past intake of specific foods and food groups. Results from a self-administered food-frequency questionnaire in a case-control study Neurology 47 1996 636 643
59. A.D. Holms, D.A. Copland, P.A. Silburn, and H.J. Chenery Acute nicotine enhances strategy-based semantic processing in Parkinson's disease Int. J. Neuropsychopharmacol. 14 2011 877 885
60. D.P. Hong, A.L. Fink, and V.N. Uversky Smoking and Parkinson's disease: does nicotine affect alpha-synuclein fibrillation? Biochim. Biophys. Acta 1794 2009 282 290
61. M.H. Hsieh, S.C. Ho, K.Y. Yeh, C.R. Pawlak, H.M. Chang, Y.J. Ho, T.J. Lai, and F.Y. Wu Blockade of metabotropic glutamate receptors inhibits cognition and neurodegeneration in an MPTP-induced Parkinson's disease rat model Pharmacol. Biochem. Behav. 102 2012 64 71
62. W.T. Hsieh, and B.H. Chiang A well-refined in vitro model derived from human embryonic stem cell for screening phytochemicals with midbrain dopaminergic differentiation-boosting potential for improving Parkinson's disease J. Agric. Food. Chem. 62 2014 6326-6236
63. S. Hunot, and E.C. Hirsch Neuroinflammatory processes in Parkinson's disease Ann. Neurol. 53 2003 49 58
64. B. Jagatha, R.B. Mythri, S. Vali, and M.M. Bharath Curcumin treatment alleviates the effects of glutathione depletion in vitro and in vivo: therapeutic implications for Parkinson's disease explained via in silico studies Free. Radic. Biol. Med. 44 2008 907 917
65. S. Jana, M. Sinha, D. Chanda, T. Roy, K. Banerjee, S. Munshi, B.S. Patro, and S. Chakrabarti Mitochondrial dysfunction mediated by quinone oxidation products of dopamine: implications in dopamine cytotoxicity and pathogenesis of Parkinson's disease Biochim. Biophys. Acta 1812 2011 663 673
66. 3 attenuates rotenone-induced neurotoxicity in SH-SY5Y cells through induction of autophagy Biochem. Biophys. Res. Commun. 451 2014 142 147
67. J. Jankovic Parkinson's disease: clinical features and diagnosis J. Neurol. Neurosurg. Psychiatr. 79 2008 368 376
68. F. Jin, Q. Wu, Y.F. Lu, Q.H. Gong, and J.S. Shi Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson's disease in rats Eur. J. Pharmacol. 600 2008 78 82
69. F. Johnson, and M.G. Kaplitt Novel mitochondrial substrates of omi indicate a new regulatory role in neurodegenerative disorders Plos One 4 2009 e7100
70. L.A. Johnson, W. Xu, K.B. Baker, J. Zhang, and J.L. Vitek Modulation of motor cortex neuronal activity and motor behavior during subthalamic nucleus stimulation in the normal primate J. Neurophysiol. 113 2015 2549 2554
71. B. Kandinov, N. Giladi, and A.D. Korczyn Smoking and tea consumption delay onset of Parkinson's disease Park. Relat. Disord. 15 2009 41 46
72. K.S. Kang, Y. Wen, N. Yamabe, M. Fukui, S.C. Bishop, and B.T. Zhu Dual beneficial effects of (-)-epigallocatechin-3-gallate on levodopa methylation and hippocampal neurodegeneration: in vitro and in vivo studies PLoS One 5 2010 e11951
73. K.S. Kang, N. Yamabe, Y. Wen, M. Fukui, and B.T. Zhu Beneficial effects of natural phenolics on levodopa methylation and oxidative neurodegeneration Brain Res. 1497 2013 1 14
74. S.S. Karuppagounder, K.S. Madathil, M. Pandey, R. Haobam, U. Rajamma, and K.P. Mohanakumar Quercetin up-regulates mitochondrial complex-I activity to protect against programmed cell death in rotenone model of Parkinson's disease in rats Neuroscience 236 2013 136 148
75. S.J. Kish, K. Shannak, and O. Hornykiewicz Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease: pathophysiologic and clinical implications N. Engl. J. Med. 318 1988 876 880
76. C. Klein, and A. Westenberger Genetics of Parkinson's disease Cold Spring Harb. Perspect. Med. 2 2012 008888
77. O. Krestinina, T. Azarashvili, Y. Baburina, A. Galvita, D. Grachev, R. Stricker, and G. Reiser In aging, the vulnerability of rat brain mitochondria is enhanced due to reduced level of 2′,3′-cyclic nucleotide-3′-phosphodiesterase (CNP) and subsequently increased permeability transition in brain mitochondria in old animals Neurochem. Int. 80 2015 41 50
78. W. Kuhn, R. Roebroek, H. Blom, D. van Oppenraaij, H. Przuntek, A. Kretschmer, T. Büttner, D. Woitalla, and T. Müller Elevated plasma levels of homocysteine in Parkinson's disease Eur. Neurol. 40 1998 225 227
79. D.W. Lee, D. Kaur, S.J. Chinta, R. Subramaniam, and J.K. Andersen A disruption in iron-sulfur center biogenesis via inhibition of mitochondrial dithiol glutaredoxin 2 may contribute to mitochondrial and cellular iron dysregulation in mammalian glutathione-depleted dopaminergic cells: implications to Parkinson's disease Antioxid. Redox Signal 11 2009 2083 2094
80. E.Y. Lee, H. Chen, J. King, and C. Charlton The role of 3-O-methyldopa in the side effects of L-DOPA Neurochem. Res. 33 2008 401 411
81. M.K. Lee, S.J. Kang, M. Poncz, K.J. Song, and K.S. Park Resveratrol protects SH-SY5Y neuroblastoma cells from apoptosis induced by dopamine Exp. Mol. Med. 39 2007 376 384
82. Y. Levites, O. Weinreb, G. Maor, M.B. Youdim, and S. Mandel Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration J. Neurochem. 78 2001 1073 1082
83. Y. Levites, M.B. Youdim, G. Maor, and S. Mandel Attenuation of 6-hydroxydopamine (6-OHDA)-induced nuclear factor-kappaB (NF-kappaB) activation and cell death by tea extracts in neuronal cultures Biochem. Pharmacol. 63 2002 21 29
84. F.J. Li, H.F. Ji, and L. Shen A meta-analysis of tea drinking and risk of Parkinson's disease Sci. World J. 2012 2012 923464
85. M.T. Lin, and M.F. Beal Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases Nature 443 2006 787 795
86. A.R. Little, and J.P. O'Callagha Astrogliosis in the adult and developing CNS: is there a role for proinflammatory cytokines? Neurotoxicology 22 2001 607 618
87. Z. Lv, H. Jiang, H. Xu, N. Song, and J. Xie Increased iron levels correlate with the selective nigral dopaminergic neurondegeneration in Parkinson's disease J. Neural. Transm. 118 2011 361 369
88. J.A. Machado-Filho, A.O. Correia, A.B. Montenegro, M.E. Nobre, G.S. Cerqueira, K.R. Neves, G. Naffah-Mazzacoratti, E.A. Cavalheiro, G.A. de Castro Brito, and G.S. de Barros Viana Caffeine neuroprotective effects on 6-OHDA-lesioned rats are mediated by several factors, including pro-inflammatory cytokines and histone deacetylase inhibitions Behav. Brain Res. 264 2014 116 125
89. J.C. Mak Potential role of green tea catechins in various disease therapies: progress and promise Clin. Exp. Pharmacol. Physiol. 39 2012 265 273
90. S. Mandel, G. Maor, and M.B. Youdim Iron and alpha-synuclein in the substantia nigra of MPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green teapolyphenol (-)-epigallocatechin-3-gallate J. Mol. Neurosci. 24 2004 401 416
91. S. Mandel, T. Amit, L. Reznichenko, O. Weinreb, and M.B. Youdim Green tea catechins as brain-permeable, natural iron chelators-antioxidants for the treatment of neurodegenerative disorders Mol. Nutr. Food Res. 50 2006 229 234
92. S.A. Mandel, T. Amit, O. Weinreb, L. Reznichenko, and M.B. Youdim Simultaneous manipulation of multiple brain targets by green tea catechins: a potential neuroprotective strategy for Alzheimer and Parkinson diseases CNS. Neurosci. Ther. 14 2008 352 365
93. P.T. Mannisto, and S. Kaakkola Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson's disease Pharmacol. Toxicol. 66 1990 317 323
94. P.T. Mannisto, and S. Kaakkola Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology and clinical efficacy of the new selective COMT inhibitors Pharmacol. Rev. 51 1999 593 628
95. N. Maswood, J. Young, E. Tilmont, Z. Zhang, D.M. Gash, G.A. Gerhardt, R. Grondin, G.S. Roth, J. Mattison, M.A. Lane, R.E. Carson, R.M. Cohen, P.R. Mouton, C. Quigley, M.P. Mattson, and D.K. Ingram Caloric restriction increases neurotrophic factor levels and attenuates neurochemical and behavioral deficits in a primate model of Parkinson's disease Proc. Natl. Acad. Sci. U. S. A. 101 2004 18171 18176
96. M.G. Maturana, A.S. Pinheiro, T.L. de Souza, and C. Follmer Unveiling the role of the pesticides paraquat and rotenone on α-synuclein fibrillation in vitro Neurotoxicology 46 2015 35 43
97. P.L. McGeer, and E.G. McGeer Inflammation and neurodegeneration in Parkinson's disease Park. Relat. Disord. 10 2004 S3 S7
98. K.S. McNaught, R. Belizaire, O. Isacson, P. Jenner, and C.W. Olanow Altered proteasomal function in sporadic Parkinson's disease Exp. Neurol. 179 2003 38 46
99. Y. Miyake, K. Tanaka, W. Fukushima, S. Sasaki, C. Kiyohara, Y. Tsuboi, T. Yamada, T. Oeda, T. Miki, N. Kawamura, N. Sakae, H. Fukuyama, Y. Hirota, M. Nagai Fukuoka- Kinki Parkinson's Disease Study Group Dietary intake of metals and risk of Parkinson's disease: a case-control study in Japan J. Neurol. Sci. 306 2011 98 102
100. A.E. Mohsen, M.M. Kuhnle, G. Rechner, A.R. Schroeter, S. Rose, S.P. Jenner, and C.A. Rice-Evans Uptake and metabolism of epicatechin and its access to the brain after oral ingestion Free Radic. Biol. Med. 33 2002 1693 1702
101. J.C. Möller, and W.H. Oertel Pramipexole in the treatment of advanced Parkinson's disease Eur. J. Neurol. 7 2000 21 25
102. V.V. Myllylä, K.A. Sotaniemi, A. Illi, K. Suominen, and T. Keränen Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease Eur. J. Clin. Pharmacol. 45 1993 419 423
103. C.-H. Ng, M.S.H. Guan, C. Koh, X. Ouyang, F. Yu, E.-K. Tan, S.P. O'Neill, X. Zhang, J. Chung, and K.-L. Lim 1,3,5-AMP kinase activation mitigates dopaminergic dysfunction and mitochondrial abnormalities in Drosophila models of Parkinson's disease J. Neurosci. 32 2012 14311 14317
104. J.W. Olney Excitotoxicity: an overview Can. Dis. Wkly. Rep. 16 1990 47 57
105. S. Papapetropoulos, C. Singer, O.A. Ross, M. Toft, J.L. Johnson, M.J. Farrer, and D.C. Mash Clinical heterogeneity of the LRRK2 G2019S mutation Arch. Neurol. 63 2006 1242 1246
106. A. Pinna, J. Bonaventura, D. Farré, M. Sánchez, N. Simola, J. Mallol, C. Lluís, G. Costa, Y. Baqi, C.E. Müller, A. Cortés, P. McCormick, E.I. Canela, E. Martínez-Pinilla, J.L. Lanciego, V. Casadó, M.T. Armentero, and R. Franco L-DOPA disrupts adenosineA(2A)-cannabinoid CB(1)-dopamine D(2) receptor heteromer cross-talk in thestriatum of hemiparkinsonian rats: biochemical and behavioral studies Exp. Neurol. 253 2014 180 191
107. Z. Pirtosek 'Bad guys' among the antiparkinsonian drugs Psychiatr. Danub 21 2009 114 118
108. A. Pisanu, D. Lecca, G. Mulas, J. Wardas, G. Simbula, S. Spiga, and A.R. Carta Dynamic changes in pro- and anti-inflammatory cytokines in microglia after PPAR-γ agonist neuroprotective treatment in the MPTPp mouse model of progressive Parkinson's disease Neurobiol. Dis. 71 2014 280 291
109. P. Poorkaj, J.G. Nutt, D. James, S. Gancher, T.D. Bird, E. Steinbart, G.D. Schellenberg, and H. Payami Parkin mutation analysis in clinic patients with early-onset Parkinson disease Am. J. Med. Genet. 129 2004 44 50
110. A. Priyadarshi, S.A. Khuder, E.A. Schaub, and S. Shrivastava A meta-analysis of Parkinson's disease and exposure to pesticides Neurotoxicology 21 2000 435 440
111. M. Quik, K. O'Leary, and C.M. Tanner Nicotine and Parkinson's disease: implications for therapy Mov. Disord. 23 2008 1641 1652
112. A. Raches, and S. Fahn O-Methyldopa interferes with striatal utilization of levodopa Ann. Neurol. 10 1981 94 95
113. A. Rahimmi, F. Khosrobakhsh, E. Izadpanah, M.R. Moloudi, and K. Hassanzadeh N-acetylcysteine prevents rotenone-induced Parkinson's disease in rat: an investigation into the interaction of Parkin and Drp1 proteins Brain. Res. Bull. 113 2015 34 40
114. A. Rakovic, A. Grünewald, J. Kottwitz, N. Brüggemann, P.P. Pramstaller, K. Lohmann, and C. Klein Mutations in PINK1 and Parkin impair ubiquitination of mitofusins in human fibroblasts PLoS. One 6 2011 e16746
115. L. Reznichenko, L. Kalfon, T. Amit, M.B. Youdim, and S.A. Mandel Low dosage of rasagiline and epigallocatechin gallate synergistically restored the nigrostriatal axis in MPTP-induced parkinsonism Neurodegener. Dis. 7 2010 219 231
116. J.R. Roede, and D.P. Jones Thiol-reactivity of the fungicide maneb Redox Biol. 2 2014 651 655
117. K.S. Saravanan, K.M. Sindhu, and K.P. Mohanakumar Acute intranigral infusion of rotenone in rats causes progressive biochemical lesions in the striatum similar to Parkinson's disease Brain Res. 1049 2005 147 155
118. D.K. Simon, M.T. Lin, L. Zheng, G.J. Liu, C.H. Ahn, L.M. Kim, W.M. Mauck, F. Twu, M.F. Beal, and D.R. Johns Somatic mitochondrial DNA mutations in cortex and substantia nigra in aging and Parkinson's disease Neurobiol. Aging 25 2004 71 81
119. + or rotenone display differential sensitivity to amphetamine and apomorphine Pharmacol. Biochem. Behav. 84 2006 321 329
120. K.M. Sindhu, K.S. Saravanan, and K.P. Mohanakumar Behavioural differences in a rotenone-induced hemiparkinsonian rat model developed following intra-nigral or median forebrain bundle infusion Brain Res. 1051 2005 25 34
121. A.B. Singleton, M. Farrer, J. Johnson, A. Singleton, S. Hague, J. Kachergus, M. Hulihan, T. Peuralinna, A. Dutra, R. Nussbaum, S. Lincoln, A. Crawley, M. Hanson, D. Maraganore, C. Adler, M.R. Cookson, M. Muenter, M. Baptista, D. Miller, J. Blancato, J. Hardy, and K. Gwinn-Hardy α-Synuclein locus triplication causes Parkinson's disease Science 302 2003 841
122. S.Y. Sit Dopamine agonists in the treatment of Parkinson s disease past, present and future Curr. Pharm. Des. 6 2000 1211 1248
123. K.J. Spinelli, V.R. Osterberg, C.K. Meshul, A. Soumyanath, and V.K. Unni Curcumin treatment improves motor behavior in α-synuclein transgenic mice PLoS One 10 6 2015 e0128510
124. R. Srividhya, K. Zarkovic, M. Stroser, G. Waeg, N. Zarkovic, and P. Kalaiselvi Mitochondrial alterations in aging rat brain: effective role of (-)-epigallo catechin gallate Int. J. Dev. Neurosci. 27 2009 223 231
125. R. Srividhya, and P. Kalaiselvi Neuroprotective potential of epigallo catechin-3-gallate in PC-12 cells Neurochem. Res. 37 2012 940 949
126. S. Sugama, T. Takenouchi, B.P. Cho, T.H. Joh, M. Hashimoto, and H. Kitani Possible roles of microglial cells for neurotoxicity in clinical neurodegenerative diseases and experimental animal models Inflamm. Allergy Drug Targets 8 2009 277 284
127. I. Sziráki, K.P. Mohanakumar, P. Rauhala, H.G. Kim, K.J. Yeh, and C.C. Chiueh Manganese: a transition metal protects nigrostriatal neurons from oxidative stress in the iron-induced animal model of parkinsonism Neuroscience 85 1998 1101 1111
128. R. Takahashi, K. Ono, Y. Takamura, M. Mizuguchi, T. Ikeda, H. Nishijo, and M. Yamada Phenolic compounds prevent the oligomerization of α-synuclein and reduce synaptic toxicity J. Neurochem. 134 2015 943 955
129. L.C.S. Tan Epidemiology of Parkinson's disease Neurol. Asia 18 2013 231 238
130. J.M. Tan, E.S. Wong, and K.L. Lim Protein misfolding and aggregation in Parkinson's disease Antioxid. Redox Signal 11 2009 2119 2134
131. K.S. Taylor, J.A. Cook, and C.E. Counsell Heterogeneity in male to female risk for Parkinson's disease J. Neurol. Neurosurg. Psychiatr. 78 2007 905 906
132. B. Thomas Parkinson's disease: from molecular pathways in disease to therapeutic approaches Antioxid. Redox Signal 11 2009 2077 2082
133. R. Tintner, and J. Jankovic Treatment options for Parkinson's disease Curr. Opin. Neurol. 15 2002 467 476
134. D. Tripathy, R. Haobam, R. Nair, and K.P. Mohanakumar Engraftment of mouse embryonicstem cells differentiated by default leads to neuroprotection, behaviour revival and astrogliosis in parkinsonian rats PLoS One 8 2013 e72501
135. S. Uchida, T. Kadowaki-Horita, and T. Kanda Effects of the adenosine A2A receptor antagonist on cognitive dysfunction in Parkinson's disease Int. Rev. Neurobiol. 119 2014 169 189
136. C.M. van Duijn, M.C. Dekker, V. Bonifati, R.J. Galjaard, J.J. Houwing-Duistermaat, P.J. Snijders, L. Testers, G.J. Breedveld, M. Horstink, L.A. Sandkuijl, J.C. van Swieten, B.A. Oostra, and P. Heutink Park7, a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36 Am. J. Hum. Genet. 69 2001 629 634
137. M. Varghese, M. Pandey, A. Samanta, P.K. Gangopadhyay, and K.P. Mohanakumar Reduced NADH coenzyme Q dehydrogenase activity in platelets of Parkinson's disease, but not Parkinson plus patients, from an Indian population J. Neurol. Sci. 279 2009 39 42
138. O. Weinreb, S. Mandel, and M.B. Youdim Gene and protein expression profiles of anti- and pro-apoptotic actions of dopamine, R-apomorphine, green tea polyphenol (-)-epigallocatechine-3-gallate, and melatonin Ann. N. Y. Acad. Sci. 993 2003 351 361
139. G.F. Wooten, L.J. Currie, V.E. Bovbjerg, J.K. Lee, and J. Patrie Are men at greater risk for Parkinson's disease than women? J. Neurol. Neurosurg. Psychiatr. 75 2004 637 639
140. X. Xie, V. Ramkumar, and L.A. Toth Adenosine and dopamine receptor interactions in striatum and caffeine-induced behavioral activation Comp. Med. 57 2007 538 545
141. X. Xu, F. Martin, and J.S. Friedman The familial Parkinson's disease gene DJ-1 (PARK7) is expressed in red cells and plays a role in protection against oxidative damage Blood Cells Mol. Dis. 45 2010 227 232
142. M. Yamada, T. Iwatsubo, Y. Mizuno, and H. Mochizuki Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease J. Neurochem. 91 2004 451 461
143. Z. Yao, and N.W. Wood Cell death pathways in Parkinson's disease: role of mitochondria Antioxid. Redox Signal 11 2009 2135 2149
144. K.A. Youdim, M.Z. Qaiser, D.J. Begley, C.A. Rice-Evans, and N.J. Abbott Flavonoid permeability across an in situ model of the Blood-brain barrier Free Rad. Biol. Med. 36 2004 592 604
145. M.B. Youdim, D. Edmondson, and K.F. Tipton The therapeutic potential of monoamine oxidase inhibitors Nat. Rev. Neurosci. 7 2006 295 309
146. W. Yu, Y. Sun, S. Guo, and B. Lu The PINK1/Parkin pathway regulates mitochondrial dynamics and function in mammalian hippocampal and dopaminergic neurons Hum. Mol. Genet. 20 2011 3227 3240
147. Y. Yu, S. Hayashi, X. Cai, C. Fang, W. Shi, H. Tsutsui, and J. Sheng Pu-erh tea extract induces the degradation of FET family proteins involved in the pathogenesis of amyotrophic lateral sclerosis Biomed. Res. Int. 2014 2014 254680